Is Egrifta (Tesamorelin) Legal in California?
HealthRX.com
Egrifta is FDA approved, with one labeled use
Key numbers
- 1.28 mgEgrifta WR labeled dose, given once daily under the WR labelSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 2 mgVial strength of the Egrifta SV product, one of the two current labeled productsSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 1.4 mgEgrifta SV labeled dose, given once daily under the SV labelSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Tesamorelin
At a glance
- FDA status / Approved prescription drug, BLA 022505, first approved November 10, 2010 [1]
- Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy [2]
- Current products / Egrifta SV 1.4 mg and Egrifta WR 1.28 mg, once daily subcutaneous, not substitutable [2][3]
- Boxed warning / None in the current SV or WR label [2][3]
- Compounding / No category-based FDA statement; not on the significant-safety-risk list [4][5][6]
- Sport / WADA prohibits it at all times under S2.2.4 [7]
What the federal approval record shows
Egrifta is tesamorelin acetate, approved on November 10, 2010 as application 022505, a new molecular entity [1]. The original new drug application was deemed a biologic license application on March 23, 2020 [1]. Two labeled products are current: Egrifta SV, a 2 mg vial, and Egrifta WR, an 11.6 mg vial, both once-daily subcutaneous injections with labels dated July 29, 2026 [2][3]. Neither label carries a boxed warning [2][3].
The approved indication is narrow. Egrifta is indicated only for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [2]. The label states that it is not indicated for weight loss management because it has a weight-neutral effect, that long-term cardiovascular safety has not been established, and that there are no data showing improved adherence to antiretroviral therapy [2]. Use in people without HIV lipodystrophy sits outside that labeled indication.
The two labeled products are not interchangeable. The Egrifta SV label gives a dose of 1.4 mg, which is 0.35 mL of the reconstituted 2 mg per 0.5 mL solution, injected subcutaneously into the abdomen once daily [2]. The Egrifta WR label gives a dose of 1.28 mg, or 0.16 mL of the reconstituted 8 mg/mL solution, once daily [3]. The labels state that Egrifta WR and Egrifta SV are not substitutable [3].
Is compounded tesamorelin legal?
FDA keeps a page of bulk drug substances that may present significant safety risks when compounded, a list for state-licensed pharmacies and physicians, and a list for outsourcing facilities. Tesamorelin appears on none of them. It is absent from the significant-safety-risk page (content dated 04/22/2026) [4], from every category of the state-licensed pharmacy and physician list (updated May 14, 2026) [5], and from every category of the outsourcing facility list (updated March 21, 2025) [6]. FDA has made no category-based statement about compounding tesamorelin.
Tesamorelin is already a component of an FDA-approved drug, Egrifta [2]. Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before they are marketed [8].
A separate HHS draft policy, filed on October 28, 2026 (Federal Register document 2026-22192, publication scheduled October 30, 2026), sets out enforcement discretion for six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. Tesamorelin is not one of the six [9][8].
Questions worth asking
Does WADA prohibit tesamorelin?
Yes. WADA's Prohibited List names tesamorelin in S2.2.4, in the growth hormone releasing factors class (GHRH and its analogues, listed alongside CJC-1293, CJC-1295 and sermorelin) [7]. It is prohibited at all times, in and out of competition, and S2 substances are non-Specified Substances [7]. It is on the 2026 List, in force since January 1, 2026, and remains on the 2027 List [7][10].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
What is Egrifta's federal legal status?
Is Egrifta legal in California?
Is compounded tesamorelin legal?
Is Egrifta approved for weight loss?
Does WADA ban tesamorelin?
What dose do the current labels give?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
Is Egrifta the same as tesamorelin?
Yes. Egrifta is the brand name for tesamorelin acetate, a new molecular entity approved by the FDA on November 10, 2010 under application 022505. Its one labeled use is reducing excess abdominal fat in HIV-infected adults with lipodystrophy.
Is tesamorelin FDA certified?
Egrifta, the brand of tesamorelin acetate, is FDA-approved. It was first approved November 10, 2010 under application BLA 022505, and the original new drug application was deemed a biologic license application on March 23, 2020.
Who is not allowed to take tesamorelin?
The labeled use is narrow: Egrifta is indicated only for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. Use in people without HIV lipodystrophy sits outside that labeled indication. Athletes are also barred, since WADA prohibits tesamorelin at all times.
References
Show all 10 referencesHide references
- Drugs@FDA: FDA-Approved Drugs.
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- Official web page.
- Official web page.
- World Anti-Doping Agency.